Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/37896
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMiyachi K.en
dc.contributor.authorChoi M.Y.en
dc.contributor.authorFritzler M.J.en
dc.contributor.authorIhar A.en
dc.contributor.authorSasse B.en
dc.date.accessioned2021-05-14T12:54:29Zen
dc.date.available2021-05-14T12:54:29Zen
dc.date.copyright2018en
dc.date.created20180925en
dc.date.issued2018-09-25en
dc.identifier.citationAnnals of the Rheumatic Diseases. Conference: Annual European Congress of Rheumatology, EULAR 2018. Amsterdam Netherlands. 77 (Supplement 2) (pp 1753), 2018. Date of Publication: June 2018.en
dc.identifier.issn1468-2060en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/37896en
dc.description.abstractBackground: The antinuclear antibody (ANA) test is often used as a screening test to aid in the diagnosis of systemic lupus erythematous (SLE and other systemic autoimmune rheumatic diseases (SARD). However, recently it was reported that a certain autoantibody referred to as anti-dense fine speckled 70 (DFS70) are much more common (up to 25%) of non-SARD and healthy individuals but rare <5%) in SLE and certain SARD. The frequency of anti-DFS70 is even lower (i.e. <1%) if monospecific anti-DFS70 antibodies are found. Some reports suggested that anti-DFFS70 are more common in younger females, suggesting that hormonal factors may be responsible for the cognate B cell response. Objective(s): The primary objective of our study was to determine the frequency of ant-DFS70 in menopausal women who were referred for evaluation of undifferentiated arthritis (UA). Method(s): 282 women including 105 with UA and an age range of 27~91 years (mean=60.3) were enrolled. Menopausal women were divided into pre-, peri-, and post-menopausal stages according to menstrual regularity. (E2), Follicle stimulating hormone (FSH), rheumatoid factor (RF), ANA (by indirect immunofluorescence (IIF) (MBL) anti-cyclic citrullinated peptide antibody (ACPA: MBL ELISA) and C-reactive protein (CRP) were included in the serology workup. Postmenopausal arthralgia was designated PoMA and perimenopausal arthralgia PeMA. Result(s): In PoMA women who received HRT for two months estradiol levels increased, FSH levels decreased and the joint pain visual analogue scale was reduced by 70%, as compared to baseline. Similarly in PeMA women, administration of 600 mg tocopherol N daily had the same efficacy as that observed in PoMA. The overall frequency of anti-DFS70 of 26.7% (28/105) in PoMA and PeMA women was significantly higher than that in UA females who were diagnosed with rheumatoid arthritis (RA) (7/65:10.8%) or primary Sjogren's syndrome (SjS) (3/31: 9.7%) (p<0.05). In addition, anti-DFS70 Ab was observed primarily in low titer (1:40 -1:160) ANA positive sera. On the other hand, higher titer ANAs (titer >1/320) were observed in the females that were diagnosed as systemic lupus erythematosus (SLE) (30%) or primary SjS (48.4%), the majority of whom had lower titers of anti-DFS70, although several sera contained both high titer ANA and anti-DFS70 (see figure). Conclusion(s): Anti-DFS70 was found in higher frequency in PeMA and PoMA women than in women who developed a defined systemic autoimmune rheumatic disease such as SLE, SjS or RA. This is the first study to suggest that the presence of this autoantibody may reflect oestrogen fluctuations or deficiency. A negative association between ANA titer and anti-DFS70 levels by ELISA remains to be confirmed in larger studies. (Table Presented).en
dc.languageenen
dc.languageEnglishen
dc.publisherBMJ Publishing Groupen
dc.titleThe frequency of anti-DFS70 autoantibodies in Japanese women with peri-and postmenopausal arthralgia.en
dc.typeConference Abstracten
dc.identifier.affiliationRheumatologyen
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1136/annrheumdis-2018-eular.2013en
local.date.conferencestart2018-06-13en
dc.identifier.source623994743en
dc.identifier.institution(Miyachi) Rheumatology and Women's Health, Keigu Clinic, Yokohama, Japan (Miyachi) Technological Development, Health Sciences Research Institute, Yokohama, Japan (Ihar) Rheumatology, Keigu Clinic, Yokohama, Japan (Sasse) Rheumatology, Monash Health, Victoria, Australia (Choi, Fritzler) Cumming School of Medicine, University of Calgary, Calgary, Canadaen
dc.description.addressK. Miyachi, Rheumatology and Women's Health, Keigu Clinic, Yokohama, Japanen
dc.description.publicationstatusCONFERENCE ABSTRACTen
local.date.conferenceend2018-06-16en
dc.rights.statementCopyright 2018 Elsevier B.V., All rights reserved.en
dc.identifier.affiliationext(Miyachi) Rheumatology and Women's Health, Keigu Clinic, Yokohama, Japan-
dc.identifier.affiliationext(Miyachi) Technological Development, Health Sciences Research Institute, Yokohama, Japan-
dc.identifier.affiliationext(Ihar) Rheumatology, Keigu Clinic, Yokohama, Japan-
dc.identifier.affiliationext(Choi, Fritzler) Cumming School of Medicine, University of Calgary, Calgary, Canada-
dc.identifier.affiliationmh(Sasse) Rheumatology, Monash Health, Victoria, Australia-
item.grantfulltextnone-
item.openairetypeConference Abstract-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
Appears in Collections:Conferences
Show simple item record

Page view(s)

14
checked on Sep 5, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.